HMN 2025: How zoledronate prevents morphometric vertebral fractures over 10 years

For early postmenopausal ladies, zoledronate administered at baseline and 5 years is efficient for stopping morphometric vertebral fracture, in accordance with a review published within the Jan. 16 difficulty of the New England Journal of Medicine.

Mark J. Bolland, M.B., Ch.B., Ph.D., from the University of Auckland in New Zealand, and colleagues carried out a 10-year potential double-blind trial involving early postmenopausal ladies (age 50 to 60 years) with bone mineral density T scores decrease than 0 and better than ?2.5 on the lumbar backbone, femoral neck, or hip.

Participants had been randomly assigned to obtain an infusion of zoledronate (5 mg) at baseline and at 5 years (zoledronate-zoledronate group), zoledronate (5 mg) at baseline and placebo at 5 years (zoledronate-placebo group), or placebo at each baseline and 5 years (placebo-placebo group).

Overall, 1,003 of the 1,054 ladies accomplished 10 years of follow-up. The researchers discovered that 6.3, 6.6, and 11.1 p.c of girls within the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo teams, respectively, had a brand new morphometric fracture (relative dangers, 0.56 and 0.59 for zoledronate-zoledronate and zoledronate-placebo, respectively, versus placebo-placebo).

The relative dangers of fragility fracture, any fracture, and main osteoporotic fracture had been 0.72, 0.70, and 0.60, respectively, and 0.79, 0.77, and 0.71, respectively, for zoledronate-zoledronate versus placebo-placebo and for zoledronate-placebo versus placebo-placebo.

“Intravenous zoledronate administered as soon as each 5 years lowered the incidence of morphometric vertebral fractures throughout a 10-year interval,” the authors write.